CIBC Private Wealth Group LLC Trims Stock Position in Edwards Lifesciences Corporation $EW

CIBC Private Wealth Group LLC lowered its position in Edwards Lifesciences Corporation (NYSE:EW) by 6.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 95,541 shares of the medical research company’s stock after selling 6,883 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Edwards Lifesciences were worth $7,430,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in shares of Edwards Lifesciences by 111.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after buying an additional 4,805,819 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after purchasing an additional 4,108,270 shares during the last quarter. Marshall Wace LLP raised its holdings in Edwards Lifesciences by 127.5% during the 2nd quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock valued at $539,303,000 after buying an additional 3,864,908 shares during the last quarter. Finally, Viking Global Investors LP purchased a new position in shares of Edwards Lifesciences in the third quarter valued at about $238,688,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on EW shares. Royal Bank Of Canada upped their price target on Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday, December 5th. Piper Sandler reissued an “overweight” rating and set a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. The Goldman Sachs Group reiterated a “buy” rating and set a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Stifel Nicolaus set a $110.00 target price on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Tuesday, January 20th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, January 21st. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $96.14.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 24,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the completion of the transaction, the vice president directly owned 21,266 shares of the company’s stock, valued at approximately $1,782,941.44. This trade represents a 53.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total transaction of $87,002.22. Following the transaction, the vice president directly owned 33,934 shares of the company’s stock, valued at approximately $2,897,284.92. This trade represents a 2.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 61,718 shares of company stock worth $5,236,281. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $82.52 on Friday. Edwards Lifesciences Corporation has a 52 week low of $65.94 and a 52 week high of $87.89. The company has a 50 day moving average price of $82.23 and a 200 day moving average price of $81.64. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $47.92 billion, a P/E ratio of 45.09, a PEG ratio of 2.15 and a beta of 0.93.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The company had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. Edwards Lifesciences’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period last year, the firm earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.